Dr.Deeksha lochab, D21647
A total of 31 eyes with corneal neovascularisation post penetrating keratoplasty were subjected to 2.5 mg/0.1 ml of subconjunctival bevacizumab in each quadrant of neovascularization. The number of corneal segments affected by neovascularisation pre and post-injection and the incidence of complications related to treatment was evaluated till six weeks. This was an experimental study, conducted from September 2015 to September 2016. 90.3% of patients had neovascularisation in all 4 quadrants, 6.5% had neovascularisation in 2 quadrants and only 3.2% had neovascularisation in only 1 quadrant. All patients were subjected to bevacizumab and at the end of 6 weeks there was a significant decrease in neovascularisation in central segments 1.97 ± 3.72 as compared to pre 5.13 ±7.12(p=0.001) and also in peripheral segments at 6 weeks 29.90 ± 15.73 as compared to pre bevacizumab 44.32 ± 17.97(p<0.001). Subconjunctival bevacizumab is effective in the treatment of corneal neovascularization.
Leave a Comment